NEW YORK, Feb. 14, 2018 /PRNewswire/ --
WallStEquities.com strives to bring the best free research to the investmentcommunity. Today we are offering reports on OVAS, PACB, CUR, and PIRS which can be accessed for free by signing up to www.wallstequities.com/registration. On Tuesday, the NASDAQ Composite ended the day at 7,013.51, up 0.45%; the Dow Jones Industrial
Waltham, Massachusetts headquartered OvaScience Inc.'s stock finished Tuesday's session 3.90% lower at $0.98 with a total trading volume of 476,540 shares. The Company's shares are trading below their 50-day moving average by 20.87%. Moreover, shares of OvaScience, which discovers, develops, and commercializes fertility treatment options for women worldwide, have a Relative Strength Index (RSI) of 37.54. Get the full research report on OVAS for free by clicking below at: www.wallstequities.com/registration/?symbol=OVAS
Biosciences of California
Shares in Menlo Park, California headquartered Pacific Biosciences of California Inc. declined 2.76%, ending yesterday's session at $2.47 with a total trading volume of 2.73 million shares, which was higher than their three months average volume of 1.06 million shares. The Company's shares are trading below their 50-day moving average by 10.21%. Moreover, shares of the Company, which designs, develops, and manufactures sequencing systems to resolve genetically complex problems, have an RSI of 41.56. Gain free access to the research report on PACB at: www.wallstequities.com/registration/?symbol=PACB
On Tuesday, Germantown, Maryland headquartered Neuralstem Inc.'s stock saw a decline of 3.18%, to close the day at $1.52. A total volume of 61,961 shares was traded. The Company's shares have advanced 38.18% in the previous three months. The stock is trading below its 50-day moving average by 18.62%. Additionally, shares of Neuralstem, which focuses on the research and development of nervous system therapies based on its proprietary human neuronal stem cells and small molecule compounds, have an RSI of 35.27. Register for your free report coverage on CUR at: www.wallstequities.com/registration/?symbol=CUR
Shares in Boston, Massachusetts headquartered Pieris Pharmaceuticals Inc. ended the day 6.42% higher at $9.45. A total volume of 1.52 million shares was traded, which was above their three months average volume of 603.04 thousand shares. The stock has gained 26.68% in the last month, 73.39% in the previous three months, and 335.48% over the last twelve months. The Company's shares are trading above their 50-day and 200-day moving averages by 34.18% and 70.30%, respectively. Furthermore, shares of Pieris Pharma, which discovers and develops Anticalin-based drugs, have an RSI of 72.18.
On January 16th, 2018, research firm H.C. Wainwright reiterated its 'Buy' rating on the Company's stock with an increase of the target price from $9 a share to $12 a share. Get the free research report on PIRS at: www.wallstequities.com/registration/?symbol=PIRS
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://wallstequities.com/legal-disclaimer/
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: firstname.lastname@example.org Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
View original content:http://www.prnewswire.com/news-releases/biotech-stocks-research-reports-released-on-ovascience-pacific-biosciences-of-california-neuralstem-and-pieris-pharma-300598569.html
SOURCE Wall St. Equities
Subscribe to our Free Newsletters!
Some drugs or therapeutic agents cause undesirable reactions in lungs, known as drug-induced ...
Sleep disorders are collectively known as ''Somnipathy.'' There are over 70 different medically ...
Unintended pregnancies are very common these days, and so one in about four pregnant women go for ...View All